Raphi Levy Sells 2,871 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,871 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the completion of the transaction, the chief financial officer owned 90,180 shares in the company, valued at $1,352,700. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, August 11th, Raphi Levy sold 17,730 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total value of $248,220.00.
• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Price Performance

Shares of DRTS opened at $14.96 on Thursday. The stock has a 50 day simple moving average of $12.74 and a 200 day simple moving average of $9.79. Alpha Tau Medical Ltd. has a 52-week low of $3.18 and a 52-week high of $15.02. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09. The firm has a market capitalization of $1.35 billion, a PE ratio of -14.38 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last announced its earnings results on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.14 million. Sell-side analysts predict that Alpha Tau Medical Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on DRTS shares. LADENBURG THALM/SH SH lifted their price target on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. HC Wainwright upped their price objective on Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Piper Sandler increased their price objective on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, May 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Friday, July 17th. Finally, Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Alpha Tau Medical presently has an average rating of “Moderate Buy” and an average price target of $12.80.

Hedge Funds Weigh In On Alpha Tau Medical

Several hedge funds have recently modified their holdings of DRTS. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical during the fourth quarter worth about $48,000. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Bank of America Corp DE boosted its holdings in shares of Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after buying an additional 21,677 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after buying an additional 17,500 shares in the last quarter. Finally, Everhart Financial Group Inc. acquired a new position in Alpha Tau Medical during the second quarter worth $126,000. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.